Klaria Pharma Holding
Klaria Pharma Holding AB is a Swedish pharmaceutical company built around its patented Alginate Film drug-delivery platform, which places well-known active substances in a rapidly dissolving oral film that attaches to the mucosa. The group develops product candidates and combination products for therapeutic areas such as migraine, opioid overdose, anaphylactic shock, cancer-related pain, and other acute conditions, with operations centered in Sweden through its subsidiary structure.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenuePatented oral mucosal film technology used to deliver active pharmaceutical ingredients.
Sumatriptan-based film formulations developed for migraine treatment.
Naloxone film formulations intended for emergency overdose reversal use.
Epinephrine film formulations designed for rapid treatment of severe allergic reactions.
Ketamine and cannabinoid-based film projects for pain and related indications.
Customers
Klaria’s customers are primarily pharmaceutical partners, licensees, distributors, and other commercial counterparties that can develop, register, manufacture, or market film-based drug products. The end-use markets are patients and healthcare systems in acute-care and specialty therapeutic areas, but the company’s direct commercial counterparties are typically industry partners rather than retail consumers. Its business model depends on counterparties that value differentiated delivery, patent protection, and the ability to pair established active ingredients with a novel dosage form.
Companies that collaborate on development, licensing, or commercialization of film-based drug candidates.
Organizations that help bring approved products to market and expand geographic reach.
Hospitals, clinics, and emergency-care settings that would use rapid-acting therapies if approved and launched.
End users for migraine, opioid overdose, anaphylaxis, and pain products once commercialized.
Counterparties involved in clinical, regulatory, and formulation work around specific product candidates.
Strategy
Klaria’s strategy is to protect and extend its Alginate Film platform through a patent portfolio and project-specific patent filings around each product combination. The company’s commercial logic is to pair its delivery technology with well-proven active substances in indications where rapid onset and differentiated administration can matter, then advance those programs through regulatory and partnership pathways.
Patent protection is central to preserving the platform's commercial value and partner appeal.
The company’s value depends on converting the platform into approved, marketable products.
External partners are important for funding, market access, and execution across regions.
Geography
Klaria is headquartered in Sweden and listed on Nasdaq First North Growth Market in Stockholm. Its patent portfolio and product-development efforts are described for Sweden, the EU/rest of the world, and the United States, reflecting a business designed for international pharmaceutical markets rather than a single domestic market.
Risks
Klaria faces the typical risks of a development-stage pharmaceutical company: regulatory approval uncertainty, clinical and manufacturing risk, and the possibility that product candidates do not reach market. Its platform also depends on patent strength and partner execution, so intellectual-property disputes, weak market uptake, or failed collaborations could materially limit commercialization.
- Regulatory approval riskImpact: CriticalLikelihood: Medium
Products require clinical evidence and approvals from authorities such as the FDA and EMA before sales can begin.
Exposure: Product candidates in multiple therapeutic areas
- Clinical development and manufacturing riskImpact: HighLikelihood: High
The company must prove safety, efficacy, and manufacturability for each candidate and market.
Exposure: All pipeline programs
- Intellectual property riskImpact: HighLikelihood: Medium
Patent coverage may be incomplete, challenged, or insufficient to block competitors.
Exposure: Alginate Film platform and combination patents
- Partner and distribution riskImpact: HighLikelihood: Medium
Growth depends on agreements with distributors and other commercial counterparties.
Exposure: Commercialization and market access
- Competition riskImpact: MediumLikelihood: Medium
Other companies may develop equivalent or better products for the same indications.
Exposure
Accounting
Judgemental itemsMilestone and performance-based payments are recognized when contractual obligations are completed, which can make revenue uneven.
Impact: Affects timing and comparability of reported sales
Capitalized development-related assets must be tested when indicators suggest recoverable value may have changed.
Impact: Can create material non-cash charges
The company notes large loss carryforwards that may not be usable if future ownership changes or profitability is uncertain.
Impact: Affects tax asset recognition and equity
Development-stage biotech companies often rely on equity financing, making share count and equity balances important.
Impact: Dilution and balance-sheet resilience
Similar listed companies
Publicly listed companies with a comparable business focus.
Lexaria Bioscience Corp.
LEXX · Pharmaceutical Preparations
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Cloetta
CLA-B · Consumer Staples
Cloetta is a prominent confectionery company in Northern Europe, known for its strong local brands in the confectionery and nuts segments.
BioGaia
BIOG-B · Health Care
BioGaia AB is a Swedish company specializing in the development, manufacturing, and marketing of probiotic products aimed at enhancing gut, oral, and immune health.
Last updated: 24/09/2026